8-K: Baxter Q3 2025: Adjusted EPS Soars, New CEO Charts Course

Baxter International Inc. reported third-quarter 2025 sales of $2.84 billion, a 5% increase, with adjusted diluted EPS of $0.69, as new CEO Andrew Hider outlines a focus on continuous improvement.

Summary

• Worldwide sales from continuing operations in the third quarter of 2025 totaled approximately $2.84 billion, increasing 5% on a reported basis and 2% on an operational basis.
• U.S. sales from continuing operations were approximately $1.54 billion, increasing 3% on a reported basis but declining 1% on an operational basis.
• International sales from continuing operations were approximately $1.29 billion, increasing 8% on a reported basis and 5% on an operational basis.
• U.S. GAAP diluted earnings per share (loss) from continuing operations was ($0.10) for the quarter.
• Adjusted diluted EPS from continuing operations was $0.69, representing a 41% increase over the prior year.
• Net income (loss) from continuing operations on a U.S. GAAP basis totaled ($51) million.
• Medical Products & Therapies segment sales declined 1% on both reported and operational bases to $1.33 billion, impacted by lower infusion pump sales and IV solutions softness.
• Healthcare Systems & Technologies segment sales increased 3% reported and 2% operational to $773 million, driven by Care & Connectivity Solutions.
• Pharmaceuticals segment sales increased 7% on both reported and operational bases to $632 million, due to strength in Drug Compounding and Injectables & Anesthesia.
• Free cash flow from continuing operations for the nine months ended September 30, 2025, was ($18) million, compared to $62 million in the prior year period.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company reported a GAAP loss and faced operational headwinds in some segments (e.g., infusion pumps, U.S. operational sales decline, negative free cash flow), the significant 41% increase in adjusted diluted EPS and the new CEO's clear strategic focus on continuous improvement and sustainable growth provide a positive outlook. The launch of new products and strong performance in other segments also contribute positively.

Positives

• Adjusted diluted EPS from continuing operations increased by a significant 41% to $0.69 in Q3 2025 compared to the prior year.
• International sales from continuing operations grew 8% on a reported basis and 5% operationally, demonstrating strong global demand.
• The Pharmaceuticals segment showed robust growth of 7% on both reported and operational bases, driven by Drug Compounding and Injectables & Anesthesia.
• Advanced Surgery products within the Medical Products & Therapies segment continued to experience strong global demand.
• Launched the Welch Allyn Connex 360 Vital Signs Monitor, a next-generation patient monitoring device with advanced connectivity and security.
• Awarded a Gold Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC) for IV Solutions, Nutrition Solutions, and Premix Drugs, being the first manufacturer to earn this distinction across these categories.
• New CEO Andrew Hider has initiated an enterprise-wide continuous improvement system to sharpen execution and strengthen future results.

Negatives

• U.S. sales from continuing operations declined 1% on an operational basis in Q3 2025.
• U.S. GAAP diluted earnings per share from continuing operations was a loss of ($0.10) for the quarter.
• Medical Products & Therapies sales declined 1% operationally, primarily due to lower infusion pump sales and softness in IV solutions, attributed to post-Hurricane Helene fluid conservation efforts.
• Free cash flow from continuing operations for the nine months ended September 30, 2025, was negative ($18) million, a decrease from $62 million in the prior year.
• Gross margin on a U.S. GAAP basis decreased to 33.5% from 38.3% in the prior year quarter.

Risks

• Ability to achieve intended benefits of strategic actions, including the Kidney Care business sale, business strategy, and cost-saving initiatives.
• Impact of global economic conditions, including changes in tariffs, taxation, trade policies, sanctions, potential recession, supply chain disruptions, inflation, interest rates, financial market volatility, and geopolitical events (Ukraine war, Middle East conflict).
• Demand and market acceptance risks for new and existing products, competitive pressures, and customer response to Novum IQ Large Volume Pump (Novum LVP) field actions and related voluntary ship and installation hold.
• Challenges with converting customers to new or alternative products and accurately predicting changing customer preferences and future expenditures.
• Product development risks, including satisfactory clinical performance, obtaining and maintaining required regulatory approvals, and manufacturing at appropriate scale.
• Future actions of, or failures to act or delays in acting by, regulatory bodies (FDA, EMA), or product quality/patient safety issues that could lead to recalls, adverse regulatory reports, or other sanctions.
• Continuity, availability, and pricing of acceptable raw materials and component parts, and the company's ability to pass increased costs to customers.
• Failure to accurately forecast or achieve shortand long-term financial performance and goals, market growth rates, customer demand, and related impacts on liquidity.
• Future downgrades to the company's credit ratings or ratings outlooks, and the related impact on funding costs and liquidity.
• Actions by tax authorities in connection with ongoing tax audits and the outcome of pending or future litigation.
• Fluctuations in foreign exchange and interest rates.
• Impact of any accounting estimates and assumptions, including with respect to goodwill, intangible assets, or other long-lived asset impairments.
• Failures with respect to the company's quality, compliance, or ethics programs.
• Inability to attract, develop, retain, and engage key employees, and the occurrence of labor disruptions.
• Inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster or severe weather events (such as Hurricane Helene).
• Breaches and breakdowns affecting the company's information technology systems or protected information, including by cyber-attack.
• The company's ability to effectively develop, integrate, or deploy artificial intelligence, machine learning, and other emerging technologies.
• Impact of physical effects of climate change, severe storms, and storm-related events.
• Changes to legislation and regulation and other governmental pressures in the United States and globally, including healthcare reform, pricing, reimbursement, and taxation policies.
• Ability to meet evolving and varied corporate responsibility expectations of stakeholders, including compliance with global sustainability regulations.
• Ability to protect or enforce the company's patents or other proprietary rights, or where third-party patents restrict the company's manufacture, sale, or use of affected products or technology.

Future Outlook

For full-year 2025, Baxter now expects sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis. Adjusted earnings from continuing operations are projected to be $2.35 to $2.40 per diluted share. For the fourth quarter of 2025, the company anticipates sales growth from continuing operations of approximately 2% on a reported basis and a decline of approximately 2% on an operational basis, with adjusted earnings from continuing operations of $0.52 to $0.57 per diluted share.

Management Comments

• "I joined Baxter because it’s a global healthcare leader – an iconic brand with an essential portfolio that touches more than 350 million patients every year."
• "In my first weeks, I’ve seen firsthand the passion and expertise that are at the heart of this company. I’ve been working side-by-side with our teams to understand what drives performance, as well as our challenges and opportunities ahead."
• "Following this work, we have already taken decisive steps, including the launch of a new enterprise-wide continuous improvement system to sharpen execution and strengthen future results."
• "There is clearly work ahead of us, but I’m energized by the team’s commitment, motivated by our potential, and confident we’ve begun taking the right steps to build a future of growth and enhanced performance."

Industry Context

Baxter operates as a global medtech leader, providing essential solutions across various healthcare settings. The company's performance reflects broader industry trends, including continued demand for connected care solutions and advanced surgical products. However, it also highlights vulnerabilities to external factors like natural disasters (Hurricane Helene's impact on IV solutions) and regulatory challenges (EU medical device regulations). The focus on continuous improvement and supply chain resiliency aligns with industry efforts to enhance operational efficiency and mitigate disruptions.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess Baxter's performance against global benchmarks.

Management Changes

Legal Proceedings

• The company's results for the nine months ended September 30, 2025, included charges related to matters involving alleged injury from environmental exposure.
• The company's results for the nine months ended September 30, 2024, included charges related to environmental reserves for remediation actions associated with historic operations at certain facilities.

Related Party Transactions

• Other sales not allocated to a segment primarily include sales to Vantive, pursuant to the Kidney Care Manufacturing and Supply Agreement (MSA), following the acquisition of Baxter's Kidney Care business by Carlyle.

Stakeholder Impact

• Shareholders: Impacted by the GAAP loss but potentially benefit from the strong adjusted EPS growth and the new CEO's focus on long-term value creation and continuous improvement.
• Patients: Benefit from the launch of new patient monitoring devices (Welch Allyn Connex 360) and Baxter's mission to save and sustain lives through its essential portfolio.
• Employees: The new CEO's focus on continuous improvement and sharpening execution may lead to organizational changes and a renewed strategic direction.
• Customers: Affected by issues like the Novum LVP ship and installation hold and potential IV solutions softness, but also benefit from new product innovations and efforts to strengthen supply chain resiliency.
• Suppliers: The continuity, availability, and pricing of raw materials and component parts remain a risk factor, potentially impacting supplier relationships and costs.

Next Steps

• Baxter will participate in the Jefferies Global Healthcare Conference on November 18, 2025, at 7 a.m. CST.
• Baxter will participate in the Evercore Healthcare Conference on December 2, 2025, at 9:50 a.m. CST.

Key Dates

Recommendation

While Baxter demonstrated strong adjusted EPS growth and has a new CEO initiating strategic improvements, the GAAP loss, operational sales decline in the U.S., negative free cash flow, and ongoing issues with infusion pump field actions present a mixed picture. The long-term potential under new leadership is promising, but a seasoned investor would likely 'hold' to observe the execution of the new continuous improvement system and the resolution of current operational challenges before making a more definitive move.

Keywords

Baxter, BAX, Medtech, Healthcare, Earnings, Q3 2025, Financial Results, Medical Devices, Infusion Therapies, Pharmaceuticals, Patient Monitoring, Supply Chain, Andrew Hider, Welch Allyn, Novum IQ